Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.42 |
| ▸ | TP53 | P04637 | 3/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.42 |
| ▸ | CCR1 | P32246 | 2/20 | 0.42 |
| ▸ | CCR5 | P51681 | 2/20 | 0.42 |
| ▸ | CCR8 | P51685 | 2/20 | 0.42 |
| ▸ | ALPL | P05186 | 1/20 | 0.42 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.42 |
| ▸ | ALPI | P09923 | 1/20 | 0.42 |
| ▸ | ALPG | P10696 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | ADORA3 | P0DMS8 | 8/20 | 0.39 |
| ▸ | NPC1 | O15118 | 4/20 | 0.36 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 3/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3294308 | 0.89 | CA12 (0.46) | KDM4ETP53TDP1MAPK1SMN1; SMN2 | |
| SCHEMBL13154435 | 0.86 | KDM4E (0.50) | KDM4ETP53TDP1MAPK1SMN1; SMN2 | |
| SCHEMBL3295246 | 0.85 | CYP11B1 (0.41) | KDM4ETP53TDP1MAPK1SMN1; SMN2 | |
| SCHEMBL13389113 | 0.85 | KDM4E (0.49) | KDM4ETP53TDP1MAPK1SMN1; SMN2 | |
| SCHEMBL13154791 | 0.84 | CCR1 (0.42) | KDM4ETP53TDP1MAPK1SMN1; SMN2 | |
| SCHEMBL13154576 | 0.83 | KDM4E (0.45) | KDM4ETP53TDP1MAPK1SMN1; SMN2 | |
| SCHEMBL3299769 | 0.83 | NPC1 (0.50) | KDM4ETP53TDP1MAPK1SMN1; SMN2 | |
| SCHEMBL13154457 | 0.82 | KDM4E (0.55) | KDM4ETP53TDP1MAPK1SMN1; SMN2 | |
| SCHEMBL13154777 | 0.82 | KDM4E (0.45) | KDM4ETP53TDP1MAPK1SMN1; SMN2 | |
| SCHEMBL13154790 | 0.81 | NPC1 (0.44) | KDM4ETP53TDP1MAPK1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2236506-A1 | Compound having triazine ring structure substituted with group and organic electroluminescent device | Hodogaya Chemical Co., Ltd. (JP) | 2010-10-06 | — | — | EP | disclosed |
| US-20100090588-A1 | COMPOUND HAVING TRIAZINE RING STRUCTURE SUBSTITUTED WITH PYRIDYL GROUP AND ORGANIC ELECTROLUMINESCENT DEVICE | HODOGAYA CHEMICAL CO., LTD. (JP) | 2010-04-15 | — | — | US | disclosed |
| US-20100090588-A1 | COMPOUND HAVING TRIAZINE RING STRUCTURE SUBSTITUTED WITH PYRIDYL GROUP AND ORGANIC ELECTROLUMINESCENT DEVICE | HODOGAYA CHEMICAL CO., LTD. (JP) | 2010-04-15 | — | — | US | disclosed |
| EP-2055704-A1 | COMPOUND HAVING TRIAZINE RING STRUCTURE SUBSTITUTED WITH PYRIDYL GROUP AND ORGANIC ELECTROLUMINESCENT DEVICE | Hodogaya Chemical Co., Ltd. (JP) | 2009-05-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100090588-A1 | COMPOUND HAVING TRIAZINE RING STRUCTURE SUBSTITUTED WITH PYRIDYL GROUP AND ORGANIC ELECTROLUMINESCENT DEVICE | SCO2, OR51E2, NONO | KDM4E 756/4885TP53 3307/4885TDP1 2408/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.